The newborn screening for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) market is growing as healthcare systems prioritize early detection of rare but serious genetic disorders. The market was valued at USD 2.09 billion in 2024 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 5.48%.wiseguyreports SMA affects motor neurons and can lead to...